Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Girard N, Minchom A, Ou SI, Gadgeel SM, et al. Clin Lung Cancer 2022;23:571-577.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Girard N, Minchom A, Ou SI, Gadgeel SM, et al. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors. Clin Lung Cancer 2022;23:571-577.
PMID: 36085282